<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00594100</url>
  </required_header>
  <id_info>
    <org_study_id>NPS 05-05</org_study_id>
    <nct_id>NCT00594100</nct_id>
  </id_info>
  <brief_title>GORE Embolic Protection With Reverse Flow</brief_title>
  <acronym>EMPiRE</acronym>
  <official_title>The Embolic Protection With Reverse Flow Study of the GORE Neuro Protection System in Carotid Stenting of Subjects At High Risk for Carotid Endarterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the 30-day safety and efficacy of the GORE Flow Reversal System when used with
      approved carotid stents to an Objective Performance Criterion derived from distal embolic
      protection studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The GORE Flow Reversal System, manufactured by W. L. Gore &amp; Associates, Inc., was developed
      as a proximal occlusion device to reverse the flow of blood in the carotid artery. It is
      designed to achieve embolic protection prior to crossing the lesion in the majority of cases
      in order to minimize the possibility of an adverse event occurrence.

      The objective of this study is to assess the safety and effectiveness of the GORE Flow
      Reversal System when used to provide embolic protection during Carotid Artery Stent (CAS)
      procedures. Subjects diagnosed with carotid stenosis requiring revascularization and are at
      high risk for adverse events from CEA are eligible to participate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Major Adverse Event (MAE) Rate</measure>
    <time_frame>Treatment through 30-day visit window</time_frame>
    <description>Number of participants with one or more Major Adverse Event (death, stroke, myocardial infarction, and/or transient ischemic attack (TIA)) through the 30-day follow-up (non-hierarchical; MAE adjudicated by independent Clinical Events Committee)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flow Reversal System Technical Success</measure>
    <time_frame>Procedure</time_frame>
    <description>Number of participants with Technical Success using the GORE Flow Reversal System (system deployed and utilized during stenting procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow Reversal System Success</measure>
    <time_frame>Procedure</time_frame>
    <description>Number of participants where the GORE Flow Reversal System was delivered, placed, reverse flow was established, and the balloon sheath and wire retrieved as outlined in the Instructions for Use without causing any adverse events during the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Success</measure>
    <time_frame>Procedure</time_frame>
    <description>Number of participants where the FDA-approved stent was successfully delivered, deployed,and delivery system removed with an attainment of &lt; 50% residual stenosis following stent placement, as assessed by the angiographic core laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>24-48 Hours Post-Procedure</time_frame>
    <description>Number of participants with Flow Reversal System and Stent Success in the absence of death, emergency endarterectomy, repeat percutaneous transluminal angioplasty (PTA)/thrombolysis of the target vessel, stroke, or myocardial infarction (MI), as determined by the Clinical Events Committee (CEC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency at 30 Days</measure>
    <time_frame>Treatment through 30-day visit window</time_frame>
    <description>Number of participants with less than 50% restenosis as determined by carotid duplex ultrasound core laboratory at 30 days post-procedure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Carotid Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>GFRS Pivotal Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE Flow Reversal System (GFRS)</intervention_name>
    <description>Carotid artery angioplasty and stenting with embolic protection</description>
    <arm_group_label>GFRS Pivotal Subjects</arm_group_label>
    <other_name>Gore Neuro Protection System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Carotid stenosis requiring revascularization and indicating either symptomatic status,
             with carotid stenosis ≥ 50% OR asymptomatic status with carotid stenosis ≥ 80%

          -  Target lesion is located in one of the following:(a) internal carotid artery (ICA) (b)
             bifurcation (c) common carotid artery (CCA) proximal to the bifurcation

          -  At Anatomic risk for adverse events from CEA (e.g. restenosis after a prior CEA) OR at
             Co-morbid risk for adverse events from CEA (e.g., unstable angina with ECG changes)

        Exclusion Criteria:

          -  Recent surgical procedure within 30 days before or after the stent procedure

          -  Uncontrolled sensitivity to contrast media

          -  Renal Insufficiency

          -  Recent evolving, acute stroke within 21 days of study evaluation

          -  Myocardial infarction within 72 hours prior to stent procedure

          -  History of a prior major ipsilateral stroke with residual neurological deficits likely
             to confound the neurological assessments (e.g., NIHSS)

          -  Neurological deficits not due to stroke likely to confound the neurological
             assessments (e.g., NIHSS)

        Angiographic Exclusion Criteria:

          -  Isolated ipsilateral hemisphere leading to subject intolerance to reverse flow

          -  Total occlusion of the ipsilateral carotid artery

          -  Pre-existing stent in the ipsilateral carotid artery OR the contralateral carotid
             artery that extends into the aortic arch

          -  Presence of a filling defect, thrombus, occlusion or &quot;string sign&quot; in the target
             vessel

          -  Severe lesion calcification restricting stent deployment

          -  Carotid stenosis located distal to target stenosis that is more severe than target
             stenosis

          -  &gt; 50% stenosis of the CCA proximal to target vessel

          -  Known mobile plaque in the aortic arch
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Clair, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>L. N. Hopkins, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Millard Fillmore Gates/Univ. of Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Millard Fillmore Gates/Univ. of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Parodi JC. Re: is flow reversal the best method of protection during carotid stenting? J Endovasc Ther. 2005 Jun;12(3):414-5.</citation>
    <PMID>15943521</PMID>
  </reference>
  <reference>
    <citation>Parodi JC, Schönholz C, Parodi FE, Sicard G, Ferreira LM. Initial 200 cases of carotid artery stenting using a reversal-of-flow cerebral protection device. J Cardiovasc Surg (Torino). 2007 Apr;48(2):117-24.</citation>
    <PMID>17410059</PMID>
  </reference>
  <reference>
    <citation>Parodi JC, Schönholz C, Ferreira LM, Mendaro E, Ohki T. &quot;Seat belt and air bag&quot; technique for cerebral protection during carotid stenting. J Endovasc Ther. 2002 Feb;9(1):20-4.</citation>
    <PMID>11958320</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>January 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <results_first_submitted>March 19, 2009</results_first_submitted>
  <results_first_submitted_qc>March 19, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2009</results_first_posted>
  <last_update_submitted>December 2, 2013</last_update_submitted>
  <last_update_submitted_qc>December 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carotid artery stenosis</keyword>
  <keyword>embolic protection device</keyword>
  <keyword>GORE Neuro Protection System</keyword>
  <keyword>GORE Flow Reversal System</keyword>
  <keyword>reverse flow</keyword>
  <keyword>proximal occlusion device</keyword>
  <keyword>GNPS</keyword>
  <keyword>Parodi</keyword>
  <keyword>EMPiRE</keyword>
  <keyword>distal embolization</keyword>
  <keyword>minimizing risks of CAS</keyword>
  <keyword>PAES</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was approved to enroll subjects from a maximum of 40 medical institutions in the United States (including public and academic research center hospitals and private practices).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>GFRS Pivotal Subjects</title>
          <description>All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Procedure</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="236"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Technical Failure</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Through 30 Days Post Procedure</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="236"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death / Reintervention / Medical Reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued Prior to Visit</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Visit - Phone Contact Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GFRS Pivotal Subjects</title>
          <description>All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="245"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.2" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.0" lower_limit="46.0" upper_limit="89.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Diabetes</title>
          <description>Patient has a history of Diabetes prior to enrollment</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Hypertension</title>
          <description>Patient has history of hypertension prior to study enrollment</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Ischemic Stroke</title>
          <description>Number of prior ischemic strokes prior to enrollment</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two or More</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Endarterectomy</title>
          <description>Timing of previous endarterectomy (CEA)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less than 1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than 1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptomatic</title>
          <description>Presence of baseline neurological symptoms within 6 months prior to study enrollment</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Symptomatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymptomatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Major Adverse Event (MAE) Rate</title>
        <description>Number of participants with one or more Major Adverse Event (death, stroke, myocardial infarction, and/or transient ischemic attack (TIA)) through the 30-day follow-up (non-hierarchical; MAE adjudicated by independent Clinical Events Committee)</description>
        <time_frame>Treatment through 30-day visit window</time_frame>
        <population>All primary endpoint evaluable subjects</population>
        <group_list>
          <group group_id="O1">
            <title>GFRS Pivotal Subjects</title>
            <description>All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Major Adverse Event (MAE) Rate</title>
          <description>Number of participants with one or more Major Adverse Event (death, stroke, myocardial infarction, and/or transient ischemic attack (TIA)) through the 30-day follow-up (non-hierarchical; MAE adjudicated by independent Clinical Events Committee)</description>
          <population>All primary endpoint evaluable subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major Ischemic Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor Ischemic Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemorrhagic Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death / Any Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial Infarction (MI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death / Stroke / MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient Ischemic Attack (TIA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall MAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The EMPiRE Study tested the null hypothesis that the true MAE rate was greater than or equal to an Objective Performance Criterion (OPC) of 11.83% versus the alternative hypothesis that the true MAE rate was less than the OPC. The sample size was calculated based on 80% power and a Type I error rate of 0.025. The OPC was calculated from results of published carotid artery stenting studies that utilized distal embolic protection systems.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>One-Sample Binomial</method>
            <method_desc>Significance test was based on a one-sample binomial test</method_desc>
            <param_type>Binomial Proportion</param_type>
            <param_value>0.054</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
            <estimate_desc>95% Confidence Interval is exact binomial using Clopper-Pearson method. Standard Error is from Normal approximation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Flow Reversal System Technical Success</title>
        <description>Number of participants with Technical Success using the GORE Flow Reversal System (system deployed and utilized during stenting procedure)</description>
        <time_frame>Procedure</time_frame>
        <population>All enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>GFRS Pivotal Subjects</title>
            <description>All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).</description>
          </group>
        </group_list>
        <measure>
          <title>Flow Reversal System Technical Success</title>
          <description>Number of participants with Technical Success using the GORE Flow Reversal System (system deployed and utilized during stenting procedure)</description>
          <population>All enrolled subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Flow Reversal System Success</title>
        <description>Number of participants where the GORE Flow Reversal System was delivered, placed, reverse flow was established, and the balloon sheath and wire retrieved as outlined in the Instructions for Use without causing any adverse events during the procedure.</description>
        <time_frame>Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GFRS Pivotal Subjects</title>
            <description>All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).</description>
          </group>
        </group_list>
        <measure>
          <title>Flow Reversal System Success</title>
          <description>Number of participants where the GORE Flow Reversal System was delivered, placed, reverse flow was established, and the balloon sheath and wire retrieved as outlined in the Instructions for Use without causing any adverse events during the procedure.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Success</title>
        <description>Number of participants where the FDA-approved stent was successfully delivered, deployed,and delivery system removed with an attainment of &lt; 50% residual stenosis following stent placement, as assessed by the angiographic core laboratory.</description>
        <time_frame>Procedure</time_frame>
        <population>All enrolled subjects with post procedure angiographic assessment of lesion stenosis</population>
        <group_list>
          <group group_id="O1">
            <title>GFRS Pivotal Subjects</title>
            <description>All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Success</title>
          <description>Number of participants where the FDA-approved stent was successfully delivered, deployed,and delivery system removed with an attainment of &lt; 50% residual stenosis following stent placement, as assessed by the angiographic core laboratory.</description>
          <population>All enrolled subjects with post procedure angiographic assessment of lesion stenosis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success</title>
        <description>Number of participants with Flow Reversal System and Stent Success in the absence of death, emergency endarterectomy, repeat percutaneous transluminal angioplasty (PTA)/thrombolysis of the target vessel, stroke, or myocardial infarction (MI), as determined by the Clinical Events Committee (CEC).</description>
        <time_frame>24-48 Hours Post-Procedure</time_frame>
        <population>All enrolled subjects with post procedure angiographic assessment of lesion stenosis</population>
        <group_list>
          <group group_id="O1">
            <title>GFRS Pivotal Subjects</title>
            <description>All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success</title>
          <description>Number of participants with Flow Reversal System and Stent Success in the absence of death, emergency endarterectomy, repeat percutaneous transluminal angioplasty (PTA)/thrombolysis of the target vessel, stroke, or myocardial infarction (MI), as determined by the Clinical Events Committee (CEC).</description>
          <population>All enrolled subjects with post procedure angiographic assessment of lesion stenosis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patency at 30 Days</title>
        <description>Number of participants with less than 50% restenosis as determined by carotid duplex ultrasound core laboratory at 30 days post-procedure.</description>
        <time_frame>Treatment through 30-day visit window</time_frame>
        <population>Subjects with successful stent placement and ultrasound evaluation at 30-day follow-up evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>GFRS Pivotal Subjects</title>
            <description>All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).</description>
          </group>
        </group_list>
        <measure>
          <title>Patency at 30 Days</title>
          <description>Number of participants with less than 50% restenosis as determined by carotid duplex ultrasound core laboratory at 30 days post-procedure.</description>
          <population>Subjects with successful stent placement and ultrasound evaluation at 30-day follow-up evaluation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days postprocedure (0-40 days given 10-day late follow-up window)</time_frame>
      <desc>AEs reported by investigative sites via Adverse Event Case Report Form (CRF), using study-specific coding. Site-reported adverse events that were potential Major Adverse Events (stroke or TIA) were adjudicated by the independent Clinical Events Committee.</desc>
      <group_list>
        <group group_id="E1">
          <title>GFRS Pivotal Subjects</title>
          <description>All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Groin Hematoma (w/wo Surgical Repair)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Other (Bleeding)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Angina/Coronary Ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure (CHF)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction (MI)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Other (Cardiac)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other (Other)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Other (Infectious/Inflammatory)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Other (Wound)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke/Cerebrovascular accident (CVA)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Cerebral ischemia/Transient ischemic attack (TIA)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Other (Neurologic)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Hyperperfusion Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Pain (Head, Neck)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Cerebral Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure/Insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Other (Surgical Procedure)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pseudoaneurysm (Femoral)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Other (Neurologic)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Pain (Head, Neck)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Other (Other)</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Gore has the right to review disclosures, requesting a delay of less than 90 days. Each investigator will postpone single center publications until after disclosure of multi-center data, less than 12 months from study completion/termination at all participating sites.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Garcia</name_or_title>
      <organization>W. L. Gore &amp; Associates</organization>
      <phone>(800) 437-8181</phone>
      <email>AGarcia@WLGore.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

